Illumina/$ILMN
1D1W1MYTD1Y5YMAX
Capital at risk
About Illumina
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
- Ticker
- $ILMN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 8,625
- Headquarters
- San Diego, United States
- Website
- www.illumina.com
Illumina Metrics
BasicAdvanced
$31B
38.77
$5.37
1.46
-
Price and volume
Market cap
$31B
Beta
1.46
52-week high
$231.81
52-week low
$88.00
Average daily volume
1.9M
Financial strength
Current ratio
1.796
Quick ratio
1.224
Long term debt to equity
0.685
Total debt to equity
0.862
Interest coverage (TTM)
9.13%
Profitability
EBITDA (TTM)
1,194
Gross margin (TTM)
67.94%
Net profit margin (TTM)
18.34%
Operating margin (TTM)
20.52%
Effective tax rate (TTM)
18.82%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
9.05%
Return on equity (TTM)
32.34%
Valuation
Price to earnings (TTM)
38.767
Price to revenue (TTM)
7.042
Price to book
11.08
Price to tangible book (TTM)
27.48
Price to free cash flow (TTM)
33.993
Free cash flow yield (TTM)
2.94%
Free cash flow per share (TTM)
6.125
Growth
Revenue change (TTM)
4.90%
Earnings per share change (TTM)
-32.10%
3-year revenue growth (CAGR)
0.25%
10-year revenue growth (CAGR)
6.86%
3-year earnings per share growth (CAGR)
-41.32%
10-year earnings per share growth (CAGR)
6.39%
What the Analysts think about Illumina
Analyst ratings (Buy, Hold, Sell) for Illumina stock.
Analyst projections of the future price of Illumina stock.
Bulls say / Bears say
Illumina delivered Q2 2026 revenue of $1.16 billion—a 9.5% year-over-year increase and 8.1% organic growth—and raised its full-year 2026 revenue guidance to $4.60–4.64 billion, reflecting strong momentum across its sequencing platforms (PR Newswire)
Placements of NovaSeq X systems exceeded 95 units in Q2, driven by multi-unit capacity expansion orders from clinical customers, affirming robust demand for Illumina’s high-throughput sequencing platform (Investing.com)
The January 30, 2026 completion of the SomaLogic acquisition for up to $425 million enhances Illumina’s multiomics strategy—new SomaScan and SomaSeq proteomics offerings are already gaining strong customer interest and expanding service revenue (Reuters via SahmCapital)
Research and applied consumables revenue declined 7% in Q2 2026 amid sustained academic funding uncertainty, and management expects mid‐ to high‐single‐digit declines in this segment through the rest of the year (MarketBeat)
As of June 28, 2026, multiple securities class‐action complaints relating to Illumina’s GRAIL acquisition remain pending—including class certification granted on May 15, 2026—exposing the company to potential damages and legal defense costs (SEC 10-Q)
Revenue from the Greater China region fell by $7 million in Q2 2026 due to export restrictions stemming from Illumina’s inclusion on China’s Unreliable Entities List, underscoring ongoing geopolitical and regulatory risks (Form 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2026.
Illumina Financial Performance
Revenues and expenses
Illumina Earnings Performance
Company profitability
Upcoming events
No upcoming events
Illumina News
AllArticlesVideos
Funds containing Illumina
AllUSDGBPEUR
Fund name | Fund size | $ILMN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 2.05% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 2.05% |
iShares Healthcare Innovation$HEAL | $1.4B | 1.62% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.62% |
iShares Healthcare Innovation£DRDR | £1B | 1.62% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.